As­cendis Phar­ma's hy­poparathy­roidism drug scores Eu­ro­pean ap­proval af­ter re­fil­ing in the US

As­cendis Phar­ma’s Yorvipath was ap­proved in Eu­rope on Mon­day, days af­ter the com­pa­ny re­filed its ap­pli­ca­tion for the hy­poparathy­roidism hope­ful in the US.

Yorvipath, al­so known as palopeg­teri­paratide, is a pro­drug of the parathy­roid hor­mone, which is made by the parathy­roid glands and con­trols lev­els of cal­ci­um in the blood.

The FDA re­ject­ed the drug ear­li­er this year af­ter reg­u­la­tors raised con­cerns about the “man­u­fac­tur­ing con­trol strat­e­gy for vari­abil­i­ty of de­liv­ered dose in the TransCon PTH drug/de­vice com­bi­na­tion,” ac­cord­ing to As­cendis. The com­pa­ny said at the time that the agency “did not ex­press con­cern” about the clin­i­cal da­ta, and no new pre­clin­i­cal or Phase III stud­ies were re­quest­ed. As­cendis re­filed its new drug ap­pli­ca­tion in the US last week af­ter get­ting some clar­i­ty at an FDA meet­ing in Au­gust.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER